TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35170026

Group type: EXPERIMENTAL
Intervention: Continuous monitoring of vital signs (heart rate, respiratory rate, peripheral oxygen saturation, blood pressure) for up to 96 hours
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Continuous monitoring of vital signs
Number of subjects: 500
Study: 35170053

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) levels in human milk
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Adjustment for other fatty acids and maternal characteristics
Number of subjects: 100
Study: 35170082

Group type: EXPERIMENTAL
Intervention: Chidamide plus prednisone, etoposide, and thalidomide (CPET regimen) for a total of eight cycles
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Chidamide plus prednisone, etoposide, and thalidomide (CPET regimen)
Number of subjects: 71
Study: 35170571

Group type: EXPERIMENTAL
Intervention: Preinjury ADHD (PADHD)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Secondary ADHD (SADHD)
Number of subjects: 284

Group type: COMPARATOR
Intervention: No ADHD
Number of subjects: 284
Study: 35170751

Group type: EXPERIMENTAL
Intervention: PARP inhibitors (PARPi) with chemotherapy
Number of subjects: 6109

Group type: COMPARATOR
Intervention: PARPi monotherapy
Number of subjects: 6109

Group type: COMPARATOR
Intervention: PARPi maintenance therapy
Number of subjects: 6109
Study: 35170772

Group type: EXPERIMENTAL
Intervention: High energy (40%), double pass helium plasma dermal resurfacing (HPDR)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: High energy (40%), double pass HPDR
Number of subjects: 55
Study: 35171146

Group type: EXPERIMENTAL
Intervention: Contoura Vision using the Wavelight EX500 excimer laser
Number of subjects: 65
Study: 35171213

Group type: EXPERIMENTAL
Intervention: LiveOne device (cuffless wristband)
Number of subjects: 34
Study: 35171350

Group type: COMPARATOR
Intervention: Cabozantinib alone
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cabozantinib and panitumumab combination therapy
Number of subjects: 29
Study: 35171362

Group type: EXPERIMENTAL
Intervention: Support for substance use risk reduction
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Support for sexual risk reduction
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Support for personal or emotional problems
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Support for tangible aid or service
Number of subjects: 306
Study: 35171658

Group type: EXPERIMENTAL
Intervention: Sapanisertib 30 mg by mouth once weekly
Number of subjects: 38
Study: 35171913

Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitors (duration: 12 months)
Number of subjects: 3896

Group type: EXPERIMENTAL
Intervention: Permanent discontinuation of P2Y12 inhibitors
Number of subjects: 3896

Group type: EXPERIMENTAL
Intervention: Doctor-driven non-adherence
Number of subjects: 3896

Group type: EXPERIMENTAL
Intervention: Risk profile change
Number of subjects: 3896

Group type: EXPERIMENTAL
Intervention: Timing of non-adherence
Number of subjects: 3896

Group type: EXPERIMENTAL
Intervention: POCE (patient-oriented composite endpoint)
Number of subjects: 3896

Group type: EXPERIMENTAL
Intervention: Independent predictors for POCE
Number of subjects: 3896
Study: 35171989

Group type: EXPERIMENTAL
Intervention: New small non-cortical infarcts (SNCIs) and large non-cortical or cortical infarcts (LNCCIs)
Number of subjects: 1227

Group type: COMPARATOR
Intervention: No new brain infarcts
Number of subjects: 1227
Study: 35172272

Group type: EXPERIMENTAL
Intervention: Palbociclib + fulvestrant
Number of subjects: 124
Study: 35172286

Group type: COMPARATOR
Intervention: 110-projection adaptive-acquisition MCFDK-reconstruction
Number of subjects: 20

Group type: COMPARATOR
Intervention: 110-projection adaptive-acquisition SMEIR-reconstruction
Number of subjects: 20

Group type: COMPARATOR
Intervention: 110-projection adaptive-acquisition
Number of subjects: 20

Group type: COMPARATOR
Intervention: All adaptive-acquisition reconstruction methods
Number of subjects: 20
Study: 35172518

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AR expression threshold ≥ 10% nuclear expression
Number of subjects: 0
Study: 35172719

Group type: EXPERIMENTAL
Intervention: Therapeutic exercise as a treatment for chronic low back pain
Number of subjects: 10

Group type: COMPARATOR
Intervention: Biomedical model of treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Misbeliefs about chronic low back pain
Number of subjects: 10
Study: 35172722

Group type: EXPERIMENTAL
Intervention: Pulmonary hemodynamics (including diastolic pressure gradient (DPG) and mixed venous oxygen saturation (SvO2))
Number of subjects: 276

Group type: COMPARATOR
Intervention: Seattle heart failure model (SHFM)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) scores
Number of subjects: 276
Study: 35172756

Group type: EXPERIMENTAL
Intervention: Musculoskeletal pain consultation
Number of subjects: 100
Study: 35173290

Group type: EXPERIMENTAL
Intervention: Nutritional status assessment at diagnosis
Number of subjects: 824
Study: 35173720

Group type: EXPERIMENTAL
Intervention: Combined kidney and hematopoietic stem cell transplantation with anti-thymocyte globulin induction, 10x 1.2 Gy total lymphoid irradiation, CD34+ cells transfusion, and donor T cells.
Number of subjects: 3
Study: 35173817

Group type: EXPERIMENTAL
Intervention: 1st line 1G/2G EGFR-TKIs (most frequently afatinib, 45%)
Number of subjects: 896

Group type: EXPERIMENTAL
Intervention: 1st line 1G/2G EGFR-TKIs
Number of subjects: 896
Study: 35174001

Group type: EXPERIMENTAL
Intervention: BP2.0 online mindfulness-based intervention
Number of subjects: 69
Study: 35174078

Group type: EXPERIMENTAL
Intervention: Primary tumor resection (PTR) after induction chemotherapy with XELOX or mFOLFOX6
Number of subjects: 140

Group type: COMPARATOR
Intervention: Chemotherapy-alone (no PTR)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Primary tumor resection (PTR)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Tumor regression grade (TRG) score of 2
Number of subjects: 140
Study: 35174220

Group type: EXPERIMENTAL
Intervention: Second peak of high-sensitivity cardiac troponin T (hs-cTnT) after myocardial infarction
Number of subjects: 192

Group type: COMPARATOR
Intervention: No second peak of high-sensitivity cardiac troponin T (hs-cTnT) after myocardial infarction
Number of subjects: 192
Study: 35174332

Group type: EXPERIMENTAL
Intervention: Virtual Reality Driving Simulator (VRDS)
Number of subjects: 11
Study: 35174366

Group type: EXPERIMENTAL
Intervention: A1HPV6 risk calculator
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: A1HPV6 components
Number of subjects: 127
Study: 35174462

Group type: EXPERIMENTAL
Intervention: Shared epitope positive (SE+) patients
Number of subjects: 926

Group type: COMPARATOR
Intervention: Shared epitope negative (SE-) patients
Number of subjects: 926
Study: 35174470

Group type: EXPERIMENTAL
Intervention: 8-week glecaprevir/pibrentasvir (G/P) therapy
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: 12-week glecaprevir/pibrentasvir (G/P) therapy
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: 8-week and 12-week glecaprevir/pibrentasvir (G/P) therapy
Number of subjects: 735
Study: 35174749

Group type: EXPERIMENTAL
Intervention: Machine learning (ML) techniques for identifying clinical phenotypes of T2D
Number of subjects: 1030
Study: 35174756

Group type: EXPERIMENTAL
Intervention: BETTER intervention
Number of subjects: 15
Study: 35174801

Group type: EXPERIMENTAL
Intervention: Deep OCT atrophy detection (deep learning-based algorithm)
Number of subjects: 127
Study: 35174809

Group type: EXPERIMENTAL
Intervention: DPED collapse
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Neovascular age-related macular degeneration
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: DPED persistence
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Mean time to DPED collapse
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Presence of hyperreflective foci
Number of subjects: 25
Study: 35175067

Group type: EXPERIMENTAL
Intervention: TUD subjects during LATER condition
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: TUD subjects
Number of subjects: 78

Group type: COMPARATOR
Intervention: NS subjects
Number of subjects: 78
Study: 35175200

Group type: EXPERIMENTAL
Intervention: 12-week Incredible Years Basic Parent Training Program (IY)
Number of subjects: 180

Group type: COMPARATOR
Intervention: American Academy of Pediatrics' Bright Future handouts (waitlist control)
Number of subjects: 180
Study: 35175229

Group type: EXPERIMENTAL
Intervention: Semaglutide injection at 2.4 mg once weekly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight management program (reduced calorie diet and increased physical activity)
Number of subjects: 0
Study: 35175355

Group type: EXPERIMENTAL
Intervention: VSV-IFNβ-NIS (1 single IV dose at DL1, DL2, DL3, and DL4)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: VSV-IFNβ-NIS (1 single IV dose at DL4)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: VSV-IFNβ-NIS (1 single IV dose across all dose levels)
Number of subjects: 15
Study: 35175362

Group type: EXPERIMENTAL
Intervention: 1-month outcomes including extended Glasgow Outcome Scale ≥ 6
Number of subjects: 1115

Group type: EXPERIMENTAL
Intervention: 1-month higher mean SF-12 physical component summary
Number of subjects: 1115

Group type: EXPERIMENTAL
Intervention: 1-month higher mean SF-12 mental component summary
Number of subjects: 1115

Group type: EXPERIMENTAL
Intervention: 1-month higher EQ5D health index
Number of subjects: 1115

Group type: EXPERIMENTAL
Intervention: Lower physical requirements in pre-injury job nature
Number of subjects: 1115

Group type: EXPERIMENTAL
Intervention: Higher educational levels
Number of subjects: 1115

Group type: EXPERIMENTAL
Intervention: Non-work-related injuries
Number of subjects: 1115

Group type: EXPERIMENTAL
Intervention: Shorter hospital length of stay
Number of subjects: 1115

Group type: EXPERIMENTAL
Intervention: No requirement for surgery
Number of subjects: 1115

Group type: EXPERIMENTAL
Intervention: Patients who could be discharged home
Number of subjects: 1115
Study: 35175381

Group type: EXPERIMENTAL
Intervention: Unimodal ultrasound ML algorithms
Number of subjects: 1288

Group type: EXPERIMENTAL
Intervention: Multi-modal ultrasound ML algorithms
Number of subjects: 1288

Group type: COMPARATOR
Intervention: Routine breast cancer diagnosis
Number of subjects: 1288
Study: 35175691

Group type: EXPERIMENTAL
Intervention: Filgrastim and PCP
Number of subjects: 33

Group type: COMPARATOR
Intervention: PCP alone
Number of subjects: 33
Study: 35176173

Group type: EXPERIMENTAL
Intervention: Automated absence seizure detection using a wearable EEG device
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Automated behavioral testing triggered by automated seizure detection
Number of subjects: 102
Study: 35176401

Group type: EXPERIMENTAL
Intervention: D124N variant of GCK
Number of subjects: 0
Study: 35176457

Group type: EXPERIMENTAL
Intervention: Pemigatinib 1-20 mg once daily intermittently (2 weeks on/1 week off; n = 70) or continuously (n = 58)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Pemigatinib
Number of subjects: 128
Study: 35176488

Group type: EXPERIMENTAL
Intervention: F1CDx (next-generation sequencing-based test)
Number of subjects: 6802

Group type: EXPERIMENTAL
Intervention: F1CDx
Number of subjects: 6802

Group type: EXPERIMENTAL
Intervention: Pemigatinib
Number of subjects: 6802
Study: 35176527

Group type: EXPERIMENTAL
Intervention: Intraoperative PCO
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 90
Study: 35176764

Group type: EXPERIMENTAL
Intervention: GEN1046 (DuoBody-PD-L1×4-1BB)
Number of subjects: 61
Study: 35176918

Group type: EXPERIMENTAL
Intervention: AngioVac System
Number of subjects: 0
Study: 35177038

Group type: EXPERIMENTAL
Intervention: Eosinophilic phenotype (≥ 300 cells/mm)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Atopic phenotype 1
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Phenotypic overlap (eosinophilic and atopic 1)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Atopic phenotype 2
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Phenotypic overlap (eosinophilic and atopic 2)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Asthma control and oral corticosteroid use patterns
Number of subjects: 101
Study: 35177040

Group type: EXPERIMENTAL
Intervention: Health TAPESTRY intervention
Number of subjects: 135
Study: 35177200

Group type: EXPERIMENTAL
Intervention: Temporary Spinal Cord Stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35177252

Group type: EXPERIMENTAL
Intervention: ClassIntra grade I
Number of subjects: 1270

Group type: EXPERIMENTAL
Intervention: ClassIntra grade II
Number of subjects: 1270

Group type: EXPERIMENTAL
Intervention: ClassIntra grade III
Number of subjects: 1270

Group type: EXPERIMENTAL
Intervention: ClassIntra grade IV
Number of subjects: 1270

Group type: EXPERIMENTAL
Intervention: ClassIntra grade
Number of subjects: 1270

Group type: COMPARATOR
Intervention: Visceral surgery
Number of subjects: 1270
Study: 35177293

Group type: EXPERIMENTAL
Intervention: Adequate dietary protein with whey protein, leucine, and vitamin D supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bioelectrical impedance analysis (BIA)
Number of subjects: 0
Study: 35177299

Group type: EXPERIMENTAL
Intervention: Pfizer vaccine
Number of subjects: 6966

Group type: EXPERIMENTAL
Intervention: Moderna vaccine
Number of subjects: 6966

Group type: EXPERIMENTAL
Intervention: J&J vaccine
Number of subjects: 6966

Group type: EXPERIMENTAL
Intervention: Participants with autoimmune disease
Number of subjects: 6966

Group type: EXPERIMENTAL
Intervention: Participants with lung disease
Number of subjects: 6966

Group type: EXPERIMENTAL
Intervention: Diabetics
Number of subjects: 6966

Group type: EXPERIMENTAL
Intervention: Participants vaccinated against influenza
Number of subjects: 6966

Group type: EXPERIMENTAL
Intervention: Overall side effect burden
Number of subjects: 6966
Study: 35177415

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of tumor-infiltrating lymphocytes (TILs) after modified lymphodepleting regimen
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Modified lymphodepleting regimen including intravenous cyclophosphamide (20 mg/kg for 3 days) and half dosage (100 mg) of PD1 antibody
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Time-course peripheral blood counts and TCR repertoire sequencing
Number of subjects: 1
Study: 35177453

Group type: EXPERIMENTAL
Intervention: Open appendectomy for children without appendiceal mass and/or abscess
Number of subjects: 1308

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy for children without appendiceal mass and/or abscess
Number of subjects: 1308

Group type: EXPERIMENTAL
Intervention: Initial non-operative treatment (intravenous antibiotics with or without percutaneous drainage) for children with appendiceal mass and/or abscess
Number of subjects: 1308

Group type: EXPERIMENTAL
Intervention: Direct appendectomy for children with appendiceal mass and/or abscess
Number of subjects: 1308

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 1308

Group type: EXPERIMENTAL
Intervention: (In)direct costs
Number of subjects: 1308
Study: 35177461

Group type: EXPERIMENTAL
Intervention: Cow's milk protein elimination diet with amino acid-based formula for 14 days
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Baseline CoMiSS of ≥12
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Receiver-operator characteristic (ROC) analysis
Number of subjects: 300
Study: 35178068

Group type: EXPERIMENTAL
Intervention: Genome sequencing for genetic diagnosis
Number of subjects: 0
Study: 35178092

Group type: EXPERIMENTAL
Intervention: Implant follow-up for a mean duration of 7.22 years
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Implant characteristics including location, bone level, and number
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Cemented retention and emergence restoration profile
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Clinical peri-implant and periodontal soft tissue statuses
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Peri-implant parameters
Number of subjects: 107
Study: 35178428

Group type: EXPERIMENTAL
Intervention: Transanal endoscopic microsurgery (TEM) followed by radiotherapy (45-50.4 Gy in 25-28 fractions)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Transanal endoscopic microsurgery (TEM) followed by radiotherapy
Number of subjects: 168

Group type: COMPARATOR
Intervention: Total mesorectal excision (TME)
Number of subjects: 168
Study: 35178432

Group type: EXPERIMENTAL
Intervention: SMS group
Number of subjects: 155

Group type: COMPARATOR
Intervention: Printed messages group
Number of subjects: 155
Study: 35178652

Group type: EXPERIMENTAL
Intervention: Culturally-targeted, fear-appeal messages designed using the Extended Parallel Processing Model (EPPM) highlighting HPV-related cancers or genital warts.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control messages (not specified in detail).
Number of subjects: 0
Study: 35178889

Group type: COMPARATOR
Intervention: S (sarcopenic)
Number of subjects: 22
Study: 35179437

Group type: EXPERIMENTAL
Intervention: Medical therapies in pregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preconception counseling and continued monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prognostic markers and targeted immunosuppression
Number of subjects: 0
Study: 35179502

Group type: EXPERIMENTAL
Intervention: mHealth intervention (smartphone app) encouraging reduction of alcohol consumption
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: mHealth intervention (smartphone app)
Number of subjects: 357
Study: 35179564

Group type: EXPERIMENTAL
Intervention: COVID-19 ARDS
Number of subjects: 602

Group type: COMPARATOR
Intervention: Non-COVID-19 ARDS
Number of subjects: 602
Study: 35179726

Group type: EXPERIMENTAL
Intervention: Compulsive exercise
Number of subjects: 4262

Group type: EXPERIMENTAL
Intervention: Body dissatisfaction
Number of subjects: 4262

Group type: EXPERIMENTAL
Intervention: Gender difference in body dissatisfaction
Number of subjects: 4262
Study: 35179774

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35180010

Group type: EXPERIMENTAL
Intervention: Navitoclax (50 mg once daily, escalating to a maximum of 300 mg once daily)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Ruxolitinib (≥ 10 mg twice daily)
Number of subjects: 34
Study: 35180296

Group type: EXPERIMENTAL
Intervention: GDM group
Number of subjects: 167

Group type: COMPARATOR
Intervention: Normal glucose tolerance group
Number of subjects: 167
Study: 35180323

Group type: EXPERIMENTAL
Intervention: Decitabine and vorinostat with FLAG chemotherapy (fludarabine, cytarabine, and G-CSF)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Decitabine and vorinostat with FLAG chemotherapy
Number of subjects: 37
Study: 35180412

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 0
Study: 35180771

Group type: EXPERIMENTAL
Intervention: E7389-LF 2.0 mg/m2 Q3W
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: E7389-LF 1.5 mg/m2 Q2W
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: E7389-LF 2.0 mg/m2 Q3W and 1.5 mg/m2 Q2W
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: E7389-LF
Number of subjects: 21
Study: 35181266

Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA)
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Short Physical Performance Battery (SPPB)
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Combination of SPPB and MoCA
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Nottingham Extended Activities of Daily Living (IADL)
Number of subjects: 544
Study: 35181498

Group type: EXPERIMENTAL
Intervention: Rezivertinib (BPI-7711) at doses of 30 mg, 60 mg, 120 mg, 180 mg, 240 mg, 300 mg once daily until disease progression, unacceptable toxicity, or patient withdrawal
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Rezivertinib (BPI-7711)
Number of subjects: 172
Study: 35181499

Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg once daily) plus durvalumab (3 or 10 mg/kg every 2 weeks) in part A
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Osimertinib plus durvalumab (10 mg/kg every 2 weeks) in part B
Number of subjects: 34
Study: 35181519

Group type: EXPERIMENTAL
Intervention: Fenestrated designs with FG ≥5 mm
Number of subjects: 430

Group type: COMPARATOR
Intervention: Fenestrations with FG ≥5 mm
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Reinforced fenestrations
Number of subjects: 430

Group type: COMPARATOR
Intervention: DBs
Number of subjects: 430
Study: 35181541

Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 0
Study: 35181666

Group type: EXPERIMENTAL
Intervention: Neratinib and fulvestrant combination therapy
Number of subjects: 5
Study: 35181700

Group type: EXPERIMENTAL
Intervention: Optimal set of biomarkers selected by LASSO (NT-proBNP, ST2, vWF, FABP4, IGFBP-1, PAI-1, PON-3, transferrin receptor protein-1, chitotriosidase-1)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard biomarkers (NT-proBNP, hs-TnT, eGFR clinically adjusted)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Extended literature-based set of acknowledged biomarkers (NT-proBNP, hs-TnT, hs-CRP, GDF-15, ST2, PAI-1, Galectin 3)
Number of subjects: 250
Study: 35182224

Group type: EXPERIMENTAL
Intervention: G-atezo-pola (obinutuzumab, atezolizumab, polatuzumab vedotin) at pola doses of 1.4 mg/kg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: G-atezo-pola (obinutuzumab, atezolizumab, polatuzumab vedotin) at pola doses of 1.8 mg/kg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: R-atezo-pola (rituximab, atezolizumab, polatuzumab vedotin)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: G-atezo-pola
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: R-atezo-pola
Number of subjects: 36
Study: 35182741

Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAAs) for hepatitis C
Number of subjects: 0
Study: 35183106

Group type: EXPERIMENTAL
Intervention: Frailty Index (FI)
Number of subjects: 598

Group type: EXPERIMENTAL
Intervention: modified Rankin Scale (mRS)
Number of subjects: 598
Study: 35183133

Group type: EXPERIMENTAL
Intervention: 12-week group-based real-life lifestyle program 'Lekker Actief' including a progressive walking program, optional muscle strengthening program, and educational session on healthy nutrition.
Number of subjects: 451

Group type: COMPARATOR
Intervention: Control group (not specified intervention).
Number of subjects: 451
Study: 35183167

Group type: EXPERIMENTAL
Intervention: Benralizumab therapy
Number of subjects: 205